Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IWWM-11 2022 | Insurance-based disparities in patients with Waldenström’s macroglobulinemia

Karan Chohan • 28 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

Karan Chohan, MD, Mayo Clinic, Rochester, MN, shares some findings from an analysis which investigated the impact of insurance-based disparities on survival outcomes in patients with Waldenström’s macroglobulinemia (WM). This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Karan Chohan

Long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy 1:51
Long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy
Karan Chohan • 18 Jun 2025
The epigenetics of MYD88 wild-type Waldenström’s macroglobulinemia 2:08
The epigenetics of MYD88 wild-type Waldenström’s macroglobulinemia
Karan Chohan • 18 Jun 2025
A real-world study evaluating combined modality therapy for early-stage Hodgkin lymphoma 1:20
A real-world study evaluating combined modality therapy for early-stage Hodgkin lymphoma
Karan Chohan • 28 Oct 2022
WM and the clinical implications of acquired von Willebrand syndrome 1:34
WM and the clinical implications of acquired von Willebrand syndrome
Karan Chohan • 28 Oct 2022

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals